RESUMEN
OBJECTIVE: To assess retrospectively the outcome and morbidity of Iridium-192 brachytherapy in the treatment of oral cancers. DESIGN: Retrospective audit of cases treated between 1981 and 1991. SETTING: Newcastle upon Tyne, England. SUBJECTS: 73 patients with oral cancer treated with Iridium-192. MAIN OUTCOME MEASURES: Local control, crude and cause specific survival, and local morbidity. RESULTS: Seventy four cases of squamous cell carcinoma of the oral cavity were treated using interstitial Iridium-192. The disease specific 5-year survival rates were 69% for T1, 67% for T2, and 0% for T3 tumours. Mortality from recurrent cancer was 20%, and from intercurrent disease was 28%. The incidence of major radiation induced morbidity was 11%, and the local control rate was 81% for T1, 69% for T2, and 50% for T3 tumours. CONCLUSION: Interstitial radiotherapy remains a viable and valuable mode of treatment for a small proportion of patients presenting with early (T1 and T2) oral cancers.
Asunto(s)
Braquiterapia , Carcinoma de Células Escamosas/radioterapia , Radioisótopos de Iridio/uso terapéutico , Neoplasias de la Boca/radioterapia , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Braquiterapia/efectos adversos , Carcinoma de Células Escamosas/secundario , Terapia Combinada , Femenino , Humanos , Metástasis Linfática , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Estadificación de Neoplasias , Estudios Retrospectivos , Terapia Recuperativa , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
Seven cases of inverted papilloma with malignant change, of the nasal cavity and paranasal sinuses, were referred to the department of radiotherapy in Newcastle between 1979 and 1990. All patients received postoperative radiotherapy, which, in three, prevented further recurrence; in the remaining four, locally recurrent disease proved resistant to both radiotherapy and chemotherapy, ultimately becoming fatal. Only one of seven patients developed cervical lymph node metastases. Postoperative radiotherapy is of value in about 40% of patients. It is most useful when only microscopic residual disease is seen. Radiotherapy and chemotherapy, when used for bulky macroscopic disease, were of no value.